AXL and sarcoma: At this moment, at least four ADCs are under clinical investigation in sarcoma addressing targets such as AXL, neural cell adhesion molecule (NCAM), receptor tyrosine kinase-like orphan receptor (ROR), and many others are being evaluated in preclinical studies [28].